These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 37868110)
1. suPAR and WT1 modify the adhesion of podocytes and are related to proteinuria in class IV lupus nephritis. Bollain-Y-Goytia JJ; Torres-Del-Muro FD; Hernández-Martínez SP; Avalos-Díaz E; Herrera-Esparza R J Transl Autoimmun; 2023 Dec; 7():100216. PubMed ID: 37868110 [TBL] [Abstract][Full Text] [Related]
2. Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. Nawata A; Hisano S; Shimajiri S; Wang KY; Tanaka Y; Nakayama T Histopathology; 2018 Jun; 72(7):1084-1092. PubMed ID: 29247494 [TBL] [Abstract][Full Text] [Related]
3. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity. Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610 [TBL] [Abstract][Full Text] [Related]
8. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. Cathelin D; Placier S; Ploug M; Verpont MC; Vandermeersch S; Luque Y; Hertig A; Rondeau E; Mesnard L J Am Soc Nephrol; 2014 Aug; 25(8):1662-8. PubMed ID: 24790179 [TBL] [Abstract][Full Text] [Related]
9. Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis. Fu R; Guo C; Wang S; Huang Y; Jin O; Hu H; Chen J; Xu B; Zhou M; Zhao J; Sung SJ; Wang H; Gaskin F; Yang N; Fu SM Arthritis Rheumatol; 2017 Aug; 69(8):1636-1646. PubMed ID: 28544564 [TBL] [Abstract][Full Text] [Related]
10. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease. Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848 [TBL] [Abstract][Full Text] [Related]
11. Increased excretion of urinary podocytes in lupus nephritis. Bollain-Y-Goytia JJ; González-Castañeda M; Torres-Del-Muro F; Daza-Benitez L; Zapata-Benavides P; Rodríguez-Padilla C; Avalos-Díaz E; Herrera-Esparza R Indian J Nephrol; 2011 Jul; 21(3):166-71. PubMed ID: 21886975 [TBL] [Abstract][Full Text] [Related]
12. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721 [TBL] [Abstract][Full Text] [Related]
13. Immune podocytes in the immune microenvironment of lupus nephritis (Review). Liu R; Wen X; Peng X; Zhao M; Mi L; Lei J; Xu K Mol Med Rep; 2023 Nov; 28(5):. PubMed ID: 37711069 [TBL] [Abstract][Full Text] [Related]
14. Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study. Bourse Chalvon N; Orquevaux P; Giusti D; Gatouillat G; Tabary T; Tonye Libyh M; Chrusciel J; Drame M; Stockton-Bliard G; Amoura Z; Arnaud L; Lorenz HM; Blaison G; Bonnotte B; Magy-Bertrand N; Revuz S; Voll RE; Hinschberger O; Schwarting A; Pham BN; Martin T; Pennaforte JL; Servettaz A Front Immunol; 2020; 11():597863. PubMed ID: 33381119 [TBL] [Abstract][Full Text] [Related]
15. Value of immunohistochemical expression of podocalyxin in active lupus nephritis. Behairy MA; Shakweer MM; El Said TW; ElGharbawy NH Nefrologia (Engl Ed); 2018; 38(1):64-72. PubMed ID: 28757276 [TBL] [Abstract][Full Text] [Related]
16. Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. Ma R; Jiang W; Li Z; Sun Y; Wei Z Lupus; 2016 Dec; 25(14):1577-1586. PubMed ID: 27147620 [TBL] [Abstract][Full Text] [Related]
18. Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis. dos Santos M; Bringhenti RN; Rodrigues PG; do Nascimento JF; Pereira SV; Zancan R; Monticielo OA; Gasparin AA; de Castro WP; Veronese FV Int J Clin Exp Pathol; 2015; 8(5):4600-13. PubMed ID: 26191151 [TBL] [Abstract][Full Text] [Related]
19. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes. Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183 [TBL] [Abstract][Full Text] [Related]
20. Tacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis. Liao R; Liu Q; Zheng Z; Fan J; Peng W; Kong Q; He H; Yang S; Chen W; Tang X; Yu X PLoS One; 2015; 10(7):e0132724. PubMed ID: 26161538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]